Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment

BMJ Case Reports
Florian Grahammer, Karl-Georg Fischer

Abstract

A 62-year-old man and a 64-year-old woman presented to our institution with acquired haemophilia A. They both developed life-threatening bleeding. Immunoadsorption using protein A columns was used to rapidly lower factor VIII inhibitor levels. Immunosuppression with steroids and the anti-CD20 antibody, rituximab, was instituted. Yet their effects were either partial or complicated by an early relapse. Repetitive cyclophosphamide administration led to a sustained immunological response. While immunoadsorption appears effective and safe to lower factor VIII inhibitor levels, it seems that further preferably randomised controlled trials are needed to establish the value of rituximab versus the standard immunosuppressive regime comprising cyclophosphamide.

Citations

Jul 9, 2016·The Cochrane Database of Systematic Reviews·Yan ZengDan Long
Aug 24, 2021·The Cochrane Database of Systematic Reviews·Tracey Remmington, Sherie Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
N KakudoN Otani
Vnitr̆ní lékar̆ství
P SmejkalJ Zavřelová
Thrombosis and Haemostasis
Adedayo A OnitiloJohn Lazarchick
Haemophilia : the Official Journal of the World Federation of Hemophilia
G Castaman, A Tosetto
© 2021 Meta ULC. All rights reserved